Arbutus Berry - Intervention Study to Evaluate the Modulation of Intestinal Microbiota and Metabolic Parameters

Diet Habit Clinical Trial

— F4F  

Official title:

Arbutus Berry - Intervention Study to Evaluate the Modulation of Intestinal Microbiota and Metabolic Parameters

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05810922
• Other study ID #: F4F- Forest for Future
• Status: Completed
• Phase: N/A
• Start date: November 8, 2022
• Est. completion date: December 22, 2022

Study information

• Verified date: March 2023
• Source: Universidade Nova de Lisboa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The tree that produces the arbutus berry, the strawberry tree, scientific name Arbutus unedo L., belongs to the family of Ericaceae. It exists in almost all of Southern Europe in arid and siliceous lands, in woods and forests and is very common in Portugal.

Known for its use in the production of liqueurs and brandy, the arbutus berry is a fruit that can be consumed in nature or incorporated in the preparation of other foods. Arbutus berry has been attributed some properties beneficial to health given its low caloric value and its high content of vitamin C and flavonoids, which is why it is considered a good source of antioxidants.

Arbutus has a high carbohydrate content (70-80% dry weight) with a relevant fiber fraction (10-30%), constituting an interesting source of vegetable protein (1-9%) and lipids (2-3%). Given this interesting nutritional composition, the hypothesis is that a daily consumption of this fruit can have an impact in health outcomes such as microbiota modulation and an improvement of metabolic parameters.

Description:

The main objective of this clinical trial is to evaluate the effect of including a daily consumption of arbutus berry on the composition and diversity of the intestinal microbiota. It is also intended to evaluate metabolic parameters to determine the impact of this intervention.

Participants will consume 50g or 200g of arbutus berry daily for 4 weeks. This study aims to provide scientific evidence regarding the impact of arbutus berry consumption on intestinal microbiota and general health improvements.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 22, 2022
• Est. primary completion date: December 22, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Caucasian.

• Age between 18 and 50 years.

• Filling informed consent.

• Body mass index (BMI) between 18,5 kg/m2 and 25 kg/m2.

Exclusion Criteria:

• Arbutus berry sensibility.

• Arbutus berry daily consumption in the month before the study begin.

• Having taken antibiotics within the 6 months prior to beginning the study.

• Use of pro/prebiotics or fiber as a dietary supplement or any food/molecule that modifies intestinal transit time 6 weeks before recruitment.

• Use of laxative 6 weeks before recruitment.

• Specific nutritional therapy (e.g. high protein).

• Excessive alcohol consumption.

• Smoking.

• Diagnosis of gastrointestinal pathology, hormonal or thyroid pathology, autoimmune diseases, chronic use of corticosteroids, psychiatric disease or Diabetes Mellitus.

• Use of proton pump inhibitors, antidiabetic drugs, insulin, or statins.

• Pregnant or breastfeeding.

• Participation in another clinical trial within the last 3 months.

Related Conditions & MeSH terms

• Diet Habit

Intervention

Other:
• arbutus berry
consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days

Locations

Country	Name	City	State
Portugal	Nova Medical School Universidade Nova de Lisboa	Lisboa

Sponsors (2)

Lead Sponsor	Collaborator
Universidade Nova de Lisboa	Associação Centro de Apoio Tecnológico Agro-Alimentar de Castelo Branco (CATAA)

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in gut microbiota characterization	Difference in gut microbiota taxonomic characterization, from baseline to the end of intervention	14 days
Primary	Changes in gut microbiota diversity	Difference in gut microbiota Shannon index, from baseline to the end of intervention	14 days
Secondary	Changes in fasting glucose	Changes in fasting glucose, measured in mg/dL, from baseline to end of intervention	14 days
Secondary	Changes in HOMA-IR	Changes in HOMA-IR from baseline to end of intervention	14 days
Secondary	Changes in HDL cholesterol	Changes in HDL from baseline to end of intervention	14 days
Secondary	Changes in total cholesterol	Changes in total cholesterol, measured in mg/dL, from baseline to end of intervention	14 days
Secondary	Changes in LDL cholesterol	Changes in LDL cholesterol, measured in mg/dL, from baseline to end of intervention	14 days
Secondary	Changes in high sensitivity PCR	Changes in high sensitivity PCR, measured in mg/dL, from baseline to end of intervention	14 days
Secondary	Changes in IL-6	Changes in IL-6, measured in pg/mL, from baseline to end of intervention	14 days
Secondary	Changes in IL-10	Changes in IL-10, measured in pg/mL, from baseline to end of intervention	14 days
Secondary	Changes in TNFa	Changes in TNFa, measured in pg/mL, from baseline to end of intervention	14 days
Secondary	Changes in adiponectin	Changes in adiponectin, measured in ng/mL, from baseline to end of intervention	14 days
Secondary	Changes in leptin	Changes in leptin, measured in ng/mL, from baseline to end of intervention	14 days
Secondary	Changes in triglycerides	Changes in triglycerides, measured in mg/dL, from baseline to end of intervention	14 days
Secondary	Changes in short chain fatty acids amount in the stool	Changes in short chain fatty acids in the stool, measured in ng/g fecal sample, from baseline to end of intervention	14 days
Secondary	Changes in alkaline phosphatase activity in the stool	Changes in alkaline phosphatase activity in the stool, measured in xx/xx, from baseline to end of intervention	14 days